Feasibility study: Phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 2, 2014, Pages 139-144

  Simard, Carl ^a   Cloutier, Marc ^a   Néron, Sonia ^a,b  

^a Recherche et Developpement   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

flow cytometry; fluorescent cell barcoding; multiple myeloma; phosphorylation; plasma cells phenotyping; Stat 1; Stat 3

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 21; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; STAT1 PROTEIN; STAT3 PROTEIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; STAT3 PROTEIN, HUMAN;

ARTICLE; BONE MARROW; CANCER PATIENT; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES;

BONE MARROW; FEASIBILITY STUDIES; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84896715740     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21142     Document Type: Article

References (35)

1. Laubach J, Richardson P, Anderson K,. Multiple myeloma. Annu Rev Med 2011; 62: 249-264.
2. Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC,. Managing multiple myeloma: The emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011; 154: 755-762.
3. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
4. (IMWG) IMWG. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
5. Kyle RA, Rajkumar SV,. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
6. Rajkumar SV, Gahrton G, Bergsagel PL,. Approach to the treatment of multiple myeloma: A clash of philosophies. Blood 2011; 118: 3205-3211.
7. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C,. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240. (Pubitemid 44408434)
8. Raja KR, Kovarova L, Hajek R,. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149: 334-351.
9. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438. (Pubitemid 351398645)
10. Johnsen HE, Bogsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, et al. Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry Part B 2010; 78B: 338-347.
11. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023.
12. Krutzik PO, Nolan GP,. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry Part A 2003; 55A: 61-70. (Pubitemid 37522508)
13. Krutzik PO, Irish JM, Nolan GP, Perez OD,. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004; 110: 206-221. (Pubitemid 38402001)
14. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP,. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228. (Pubitemid 38962577)
15. Krutzik PO, Nolan GP,. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006; 3: 361-368.
16. Kotecha N, Krutzik PO, Irish JM,. Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom 2010;Chapter 10:Unit10 17.
17. Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E, Tsezou A,. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007; 48: 2196-2203. (Pubitemid 350091062)
18. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H,. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002; 99: 3756-3762. (Pubitemid 34534548)
19. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF,. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78: 106-113. (Pubitemid 37021949)
20. Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang Y, Chang W, Zhu Z, Feng Y, Wu D,. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 2010; 150: 543-553.
21. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L,. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Pt 2): 297-314. (Pubitemid 28448572)
22. Hirano T, Ishihara K, Hibi M,. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-2556. (Pubitemid 30339210)
23. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV,. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007; 13: 6926-6932. (Pubitemid 350276871)
24. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. (Pubitemid 29077388)
25. Zhang J, Chen F, Li W, Xiong Q, Yang M, Zheng P, Li C, Pei J, Ge F,. 14-3-3zeta interacts with stat3 and regulates its constitutive activation in multiple myeloma cells. PLoS One 2012; 7: e29554.
26. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K,. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003; 22: 8797-8801. (Pubitemid 38010503)
27. Rajkumar SV,. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009; 15: 5606-5608.
28. Fuhler GM, Diks SH, Peppelenbosch MP, Kerr WG,. Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention. Mol Med 2011; 17: 790-798.
29. Gravitz L,. Diagnostics: The early bird. Nature 2011; 480: S36-37.
30. Kumar S, Rajkumar SV,. Will the real myeloma please stand up? Leukemia 2013; 27: 760-761.
31. Auffray C, Chen Z, Hood L,. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009; 1: 2.
32. Bazzi M, Badros A,. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials. Cancer Biol Ther 2010; 10: 830-838.
33. Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR,. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996; 26: 113-120. (Pubitemid 26238183)
34. Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, Morice WG, Rajkumar SV,. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013; 27: 680-685.
35. Korde N, Kristinsson SY, Landgren O,. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573-5581.